Trial Profile
CD19-CAR-T2 Cells for Relapse/Refractory CD19 Positive Acute Leukemia-a Phase I Trial
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs CD19-chimeric-antigen-receptor-T2-cell-therapy-Guangdong-Zhaotai-InVivo (Primary)
- Indications B-cell leukaemia
- Focus Adverse reactions
- 19 Sep 2017 New trial record